Orexo AB
556500-0600ActiveDeveloping innovative medicines using proprietary drug delivery technology.
Oversigt
- 50–99
- Medarbejdere
- 100–500mio SEK
- Omsætning
- 1994
- Grundlagt
Nøglebeslutningstagere
Nikolaj Sørensen
President and CEO
Greta Alina Kampe
Director Business Development
Lena Wange
IR & Corporate Communications Director
Jonas Sävmarker
Scientific Director
+16 flere kontakter i Funnelfeedr
Beskrivelse
Orexo is a Swedish biotechnology company focused on advancing treatments for severe diseases and developing life-saving rescue medications. The core of their innovation lies in their proprietary AmorphOX ® drug delivery technology. This technology significantly improves the bioavailability and stabi...
Tags
Nøgleord
Teknologistak
Virksomhedsoplysninger
- Branche
- Annan naturvetenskaplig och teknisk forskning och utveckling
- Juridisk form
- Aktiebolag
- Momsnummer
- SE556500060001
- Adresse
- BOX 303, 751 05, UPPSALA, SE
Beslutningstagere
20 kontakter i FunnelfeedrNikolaj Sørensen
President and CEO
Greta Alina Kampe
Director Business Development
Lena Wange
IR & Corporate Communications Director
Jonas Sävmarker
Scientific Director
Raheleh Nassaji
SVP Business Development
Robert A. DeLuca
President Orexo US Inc.
Fredrik Järrsten
EVP & Chief Financial Officer
Robert Coburn
Head of Business Development
Lisa Moore
SVP Product and Portfolio Strategy
Robert DeLuca
President of Orexo US Inc.
Robert Rönn
SVP Head of R&D
Salem Tewolde
Head of Supply Chain
Robin Evers
Board member
Edward Kim
SVP Chief Medical Officer
Cecilia Coupland
SVP Head of Operations
Staffan Lindstrand
Board member
Christine Rankin
Board member
Fred George Wilkinson
Board member
Dr. Friedrich von Bohlen und Halbach
Chairman of the Board
Andre kontakter
Anneli Wennman
Senior Analytical Chemist
Lignende virksomheder
20 lignende virksomheder i Funnelfeedr
INSTITUT PRODUITS SYNTHESE (IPSEN) AB
6 medarbejdereGlobal biopharma accelerating innovative medicines for high unmet needs.
VIFOR PHARMA NORDISKA AB
Global leader developing innovative therapies for iron deficiency and kidney disease.
Cereno Scientific AB
10–19 medarbejderePioneering disease-modifying treatments for rare cardiovascular and pulmonary diseases.
Oblique Therapeutics AB (publ)
10–19 medarbejdereInnovative biotech developing breakthrough antibodies using the AbiProt platform.
BioCryst Sweden filial till BioCryst Ireland Limited
1–4 medarbejdereGlobal biotech developing novel oral medicines for rare diseases.
Udforsk mere
Spørgsmål om Orexo AB
Vil du se Funnelfeedr i aktion?
Book en gratis demo og opdag, hvordan Funnelfeedr hjælper dig med at finde og konvertere dine ideelle kunder.
Book en demo